Olympian Clinical Research

NOVEMBER 16, 2022

According to the American Academy of Dermatology , scientists believe that when a hair follicle becomes clogged with keratin, bacteria breed within it. When a hair follicle has more keratin and bacteria than it can hold, it bursts, causing the cyst-like breakout associated with HS.

Clinical Research 52

Clinical Research Bacteria Dermatology Immune Response 52

The Pharma Data

FEBRUARY 22, 2021

Discovered and developed by AbbVie scientists, RINVOQ is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. European Academy of Dermatology and Venerology Congress. About Upadacitinib (RINVOQ). 3 In August 2019 , RINVOQ received U.S. Pipeline – Our Science | AbbVie.

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

AUGUST 5, 2021

About Upadacitinib (RINVOQ ® ) 4 Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Additional endpoints at week 24 included EASI 75, EASI 90, EASI 100 and improvement from baseline Worst Pruritus NRS (weekly average).

Medicine 52

Medicine Dermatology Bacteria Vaccine 52

XTalks

AUGUST 2, 2023

2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. AbbVie’s total global revenue for Humira was $21.24 billion in 2022. Astellas Pharma Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98